2. Since carcinogens are chemicals, they can lodge themselves into the sides of the DNA ladder, and this is why they prevent the hydrogen bonds in the bases, or rungs of the ladder, from reforming: they act as a counter force to the action of the hydrogen bonds. Hydrogen bonds are weak, and the carcinogen residing in the sides of the ladder literally works to pull apart, or torque open, these weak bonds.
3. The hydrogen bonds can’t reform, so the open-ended ladder is susceptible to the DNA polymerase which is going to do the job it’s supposed to do: make copies of the open-ended rungs of the ladder. So you get an out-of-control copying of the same unzipped DNA molecule.
4. When the DNA in a cell doesn’t zip itself back up, a cell’s preprogrammed apoptosis somehow gets dismantled. In other words, the cell doesn’t kill itself. It keeps replicating infinitely— the hallmark of a cancer cell. This is what Dr. Beljanski labeled as “destabilization of DNA,” a phenomenon which deals exclusively with the secondary structure of the DNA. Its importance cannot be understated. The disruption of the secondary structure of the DNA double helix is a central factor in the creation of cancer. This is revolutionary, and it is a discovery that is “ripe for rediscovery and reappraisal.” In fact, some twenty-five years after Mirko Beljanski first made his observation about the secondary structure and the destabilization of DNA, these phenomena are now being described by many others in the scientific community.
Beljanski’s Achievements
This point cannot be stressed strongly enough. Dr. Beljanski made a major discovery when he observed and described destabilization of DNA. First, he observed that when the separation of tightly bound strands of DNA in cellular tissue are contaminated with carcinogens, the result is that the separated strands of the double helix fail to reform in the perfect corkscrew-shaped helix. This failure causes destabilization of the DNA molecule. Second, the destabilized molecule then starts replicating itself over and over with no end, and this causes the cells that contain the destabilized DNA to start replicating themselves over and over with no end. When more carcinogens enter the area, more destabilization of more DNA molecules occur. More cells begin replicating out of control, and eventually a cancerous tumor develops. As of yet, oncologists do not appear to have adopted Beljanski’s cancer-causation finding: that destabilization of DNA is the underlying source of cancer. Consequently, the cause of cancer continues to elude them.
Drs. Watson, Crick, and Wilkins deserved their 1962 Nobel Prize in physiology because they provided all humans with an enormous advancement in understanding the basis of life. Dr. Mirko Beljanski deserved, but never won and can never win, a similar Nobel Prize for tracing the cause of environmental cancer at its core, in the DNA of our cells. Hopefully, history will somehow rectify this mistake.
Case Study: Thyroid Cancer
I met French homemaker, Josiane Chardonnet (Mme. Chardonnet), at the CIRIS picnic, and we discussed the reasons why she had undergone three operations for the removal of thyroid cancer. Mme. Chardonnet’s carcinoma of the thyroid gland kept returning and excisions were required to be performed in 1972, 1975, and 1994. The last operation she underwent removed a giant tumor nine centimeters (cm) (3 1/2 inches) in length and seven cm (23/4 inches) in diameter. This last operative procedure brought some bad news with it.
Her cancer surgeon explained that he would perform no more surgeries if Mme. Chardonnet’s thyroid tumor returned again. He declared that the interior throat scarring was too great and healing could never take place; thus, any kind of chronic, open ulcer deep in her throat was destined to become infected and that infection definitely would kill her.
There are four types of thyroid malignancies, but Mme. Chardonnet does not know which type she was afflicted with because she never had access to any of the pathology reports relating to her lesions. However, it was made clear by her surgeon and her family physician who practiced internal medicine that she did have thyroid cancer and not a benign thyroid nodule. Because of the size of the third thyroid tumor, Mme. Chardonnet understood that her prognosis was not good.
Josiane Chardonnet affirmed that she needed to carry on an intensive non-toxic, anticancer program in order to prevent a recurrence. Her time was limited. It was then that Mme. Chardonnet heard about Dr. Beljanski’s discoveries from both her longtime family physician and the cancer surgeon, both of whom recommended that she take them. The two doctors had suggested these various herbal extracts both for surgical site repair and for purposes of tumor prevention.
Mme. Chardonnet began using three of the herbs immediately after learning about them. Her family physician acquired Beljanski’s botanicals for his patient. After speaking with Dr. Beljanski at that time in 1994, the patient’s two physicians advised her about the biochemist’s recommended quantities of each extract.
Mme. Chardonnet’s treatment procedure with herbs was a new strategy in oncology therapy for both of her physicians. Together they made their recommendations as to Mme. Chardonnet’s cancer treatment based on what they had heard about remarkable recoveries of patients who had been expected to die very quickly. Anecdotes were circulating about people who were then cancer-free after learning there was no hope of recovery. The two physicians knew very well that Dr. Beljanski was a Ph.D. in biochemistry and not a practicing medical doctor. In 1994, there was still a lack of clinical studies for Beljanski’s products, but the surgeon and the internist were willing to risk criticism from their peers in order to help save the life of their patient.
From taking these three products, Mme. Chardonnet has remained happy and well with no sign of thyroid cancer recurrence. When last I checked on her, it was sixteen years since she had that giant tumor removed. She is flourishing. She performs her housework with vigor and continues to take Beljanski’s supplements at the same dosage her doctors prescribed. Many patients feel reassured by continuing to take these products, believing that they are reducing the risk of cancer recurrence. Since Dr. Beljanski’s products do not have any negative side effects, such practice is safe.
3
The Oncotest:
Beljanski’s Cancer Prediction Method
A
ny good scientist knows that no matter what they uncover at their laboratory bench, from small discoveries to momentous breakthroughs, more questions will follow. Fleming finds penicillin on a petri dish, and the medical community has to then figure out how to use it. Crick, Watson, and Wilkins figure out the double helix of DNA, and that led to over fifty years of massive research into the human genome— the complete set of DNA for the human body, also known as the DNA blueprint.
Dr. Mirko Beljanski was always up for the challenge of “what’s next.” For Beljanski, once he figured out how DNA destabilization works, the all-important next question became: what if he could take that same mechanism and devise a simple yet very accurate test to identify compounds that could cause and promote destabilization of DNA in a test tube? In other words, what if he could test to see what substances were carcinogenic based on what they did to DNA in a cell?
That would be the ultimate cancer preventative, and the game was on.
The test he developed is called the
Oncotest
. John Hall, Ph.D., writing for the
Townsend Letter for Doctors and Patients
in 2004, reports that the Oncotest, “stands as an elegant, though under-appreciated, development in the history of cancer research.”
It is a test that can easily and clearly show the carcinogenicity (the ability to cause cancer) of any substance, natural or man-made. It is a very fast test and it is also inexpensive. So why is it ignored?
What is even more remarkable is that Dr. Beljanski made his findings very clear and accessible to the oncological community in his 1983 book,
Regulation of DNA Replication and Transcription.
Unfortunately for the Oncotest, I think it is too accurate, too easy and inexpensive.
There are many people who don’t want the consuming public to know what is and what isn’t truly carcinogenic.
But no matter what any business, corporation, or government wants to hide, the validity of the Oncotest is scientifically proven. As Beljanski’s second major scientific discovery, it further helps us understand not only how cancer is created at the cellular level, but also opens the door to a reliable and successful handling of the disease.
The Ames Test for the Screening of Carcinogens
One of the main reasons the Oncotest has been so steadfastly ignored, even in this second decade of the twenty-first century, has to do with the same reason Dr. Beljanski’s important multi-breakthroughs in cancer DNA have been largely unrecognized. As Robert A. Weinberg, founder of the Whitehead Institute for Cancer Research and a biology professor at MIT, says in his 1999 book,
One Renegade Cell: How Cancer Begins
, scientists are “now certain” that cancer is caused when genes are damaged through a succession of mutations.
We know that isn’t correct because destabilization can happen with environmental substances that don’t create mutations.
The scientific community has its blind spots, just like anyone does, and it continues to persist in the notion that cancer only comes from mutations. But to privilege mutations means that you are only looking at the
primary
structure of DNA—the sugar-phosphate sides of the ladder held together with a strong covalent bond—not the secondary structure. The secondary structure is the rungs of the ladder made up of the two base pairs—C/G or A/ T—held together by the weaker hydrogen bonds and is the part of DNA that is involved in replication. It is in this part that DNA destabilization occurs, and it is in the secondary structure that you can test for carcinogenic substances.
In 1973, the Ames test was developed, and it looked only at the mutations that happen in a certain bacterium.
The Ames test was quickly adopted by biochemists and the pharmaceutical industry in that same year and is still widely used by them to this day. Actually first named the
Salmonella mutagenic test
, it was devised by the then thirty-three-year-old American biologist Bruce Ames, Ph.D.
The Ames test is widely applied for screening chemicals occurring in the environment to determine their possible mutagenic activity. While in some cases it reflects carcinogenicity, it was and still is only about 68 percent to 78 percent accurate—and only on carcinogenic substances that promote mutations. Dr. Ames’ test determines the effects of a chemical on the rate of mutation in bacterial (Salmonella) microorganisms, which indicate the chemical’s likely potential for causing cancer in other living organisms, including humans.
The Ames test works in the following manner: the chemical in question is applied to plates containing growth media for bacteria which lacks the amino acid histidine (a basic amino acid found in many proteins). The growth media on the plates are also inoculated with a special mutant strain of
Salmonella typhimurium
, which requires the amino acid histidine for growth. (The usual wild strain of Salmonella typhimurium is capable of making its own histidine, but this mutant strain is unable to do so.) Cells that mutate back to the wild type, as a consequence of the mutagenic effect of the chemical being tested, are detected by the occurrence of colonies able to synthesize their own histidine and, therefore, able to grow on the media without the amino acid.
Results are obtained in about a week. However, Ames himself realized the limitations of his screening test since it was based only on mutations that occur in these bacteria in the presence of certain chemicals. Ames and others realized that at least 30 percent of known carcinogens are not mutagenic in nature. Some, including Beljanski, knew that nearly 50 percent of carcinogenic substances escape detection by the Ames test. Dr. Beljanski was skeptical of the Ames test for another reason. He doubted that all mutagenic compounds of various biochemical structures would always induce the exact same type of mutation. This skepticism combined with the fact that so many carcinogenic substances were known not to be mutagenic compelled him to look for a different or complementary explanation.
Carcinogenesis (that which initiates and promotes cancer) is a process Dr. Beljanski was able to initiate in numerous laboratory experiments even when using non-mutagenic compounds. He then compared his lab-produced cells to actual cancer cells removed from living plants, mice, and humans. He found no difference. The idea for the Oncotest was born. Invented around 1976 and described for the first time in a science journal article in 1979, the Oncotest was radically different from all tests existing up to that year.
The Oncotest and Its Advantages
To understand the workings of Dr. Beljanski’s Oncotest for identifying carcinogens, we will examine how it functions. Like the Ames test, the Oncotest is an
in vitro
test meaning that it happens in test tubes. It’s a method for screening substances for carcinogenic activity based on the hydrogen bonds not reforming in DNA replication.
The idea for the Oncotest came from the wide use of testing of normal cell DNA duplication. This examination method has acquired an often-referenced scientific name: the
Polymerase Chain Reaction
, commonly referred to in biochemistry as the
PCR
. It’s what the scientists used as a diagnostic technique in
Jurassic Park
and is used in the popular T.V. series,
CSI
.
When Dr. Beljanski employed the PCR, it was a new tool, but our intrepid researcher quickly figured out another use for it. He used it to compare the different effects of various molecules on purified healthy-cell DNA versus cancer-cell DNA.